Tag Archives: type-industry &amp; policy

No account yet? Register

Corvus Pharmaceuticals Discontinues Phase III Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Corvus Pharmaceuticals, Inc. announced that it has discontinued its Phase III study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations.

[Corvus Pharmaceuticals, Inc.]

No account yet? Register

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Vir Biotechnology, Inc. announced that the first patient has been dosed in the Phase II MARCH trial evaluating VIR-2218 together with VIR-3434 for the treatment of patients with chronic hepatitis B virus infection- a combination designed to achieve a functional cure.

[Vir Biotechnology, Inc.]

No account yet? Register

FDA Adds New Warning on Johnson & Johnson Vaccine Related to Rare Autoimmune Disorder

The Food and Drug Administration announced a new warning for the Johnson & Johnson coronavirus vaccine, saying the shot has been linked to a serious but rare side effect called Guillain-Barré syndrome, in which the immune system attacks the nerves.

[The Washington Post]

No account yet? Register

New NIH Research Initiative Supported by LFA Focuses on the Causes of Inflammation and Clinical Disease

The Lupus Foundation of America has renewed its support for the National Institutes of Health (NIH) Accelerating Medicines Partnership (AMP) which recently announced a new initiative to discover the causes of inflammation and clinical disease. The new AMP Autoimmune and Immune-Mediated Diseases (AMP AIM) Program will use novel analytics to examine the interaction among innate and adaptive immune cells and tissue-resident cells.

[The Lupus Foundation of America]

No account yet? Register

Lilly and Incyte Provide Update on Supplemental New Drug Application for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis

Eli Lilly and Company and Incyte announced that the US FDA will not meet the Prescription Drug User Fee Act action date for the supplemental new drug application for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

[Eli Lilly and Company, Inc.]

No account yet? Register

New Clinical Study Investigates Using Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients

Perspectum announced that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing is underway.

[Perspectum, Inc.]

No account yet? Register

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

TransMedics Group, Inc. announced that after review and discussion of TransMedics’ clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the US FDA has issued a favorable vote in support of approval of the OCS Liver System.

[TransMedics Group, Inc. (BioSpace, Inc.)]

No account yet? Register

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

Arch Biopartners Inc. announced that the Government of Canada has awarded a contribution of up to $6.7 million from the department of Innovation, Science and Economic Development to support the Phase II development of Metablok, the Company’s therapeutic drug candidate to prevent organ inflammation and injury in patients hospitalized with COVID-19.

[Arch Biopartners Inc.]

No account yet? Register

Galapagos Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV reported topline results with GLPG3970 in three patient studies. Phase IIa randomized 31 biologic-naïve patients with moderate to severely active ulcerative colitis in a two to one ratio, GLPG3970 to placebo.

[Galapagos NV (Globe Newswire, Inc.)]

No account yet? Register

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Vyant Bio, Inc. announced that its wholly-owned subsidiary, StemoniX, Inc. was issued US Patent No. 11054408, titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States Patent and Trademark Office.

[Vyant Bio, Inc.]